Who are CAPOXIRI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FOLFOX4 or XELOX, CAPOX chemotherapy, S-1 plus CDDP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capoxiri.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CAPOXIRI — Competitive Intelligence Brief

CAPOXIRI (CAPOXIRI) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy (fluoropyrimidine + platinum agent). Area: Oncology.

phase 3 Combination chemotherapy (fluoropyrimidine + platinum agent) Thymidylate synthase (capecitabine); DNA (oxaliplatin cross-linking) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CAPOXIRI (CAPOXIRI) — National Cancer Center Hospital East. CAPOXIRI is a combination chemotherapy regimen that inhibits DNA synthesis and repair through multiple mechanisms to kill rapidly dividing cancer cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CAPOXIRI TARGET	CAPOXIRI	National Cancer Center Hospital East	phase 3	Combination chemotherapy (fluoropyrimidine + platinum agent)	Thymidylate synthase (capecitabine); DNA (oxaliplatin cross-linking)
FOLFOX4 or XELOX	FOLFOX4 or XELOX	Federation Francophone de Cancerologie Digestive	phase 3	Combination chemotherapy (fluoropyrimidine + platinum agent)	Thymidylate synthase (5-FU/capecitabine); DNA (oxaliplatin cross-linking)
CAPOX chemotherapy	CAPOX chemotherapy	Sun Yat-sen University	phase 3	Combination chemotherapy (fluoropyrimidine + platinum agent)	Thymidylate synthase (capecitabine/5-FU); DNA (oxaliplatin)
S-1 plus CDDP	S-1 plus CDDP	Taiho Pharmaceutical Co., Ltd.	phase 3	Combination chemotherapy (fluoropyrimidine + platinum agent)	Thymidylate synthase (S-1); DNA (CDDP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy (fluoropyrimidine + platinum agent) class)

Federation Francophone de Cancerologie Digestive · 1 drug in this class
National Cancer Center Hospital East · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CAPOXIRI — Competitive Intelligence Brief. https://druglandscape.com/ci/capoxiri. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab